生物活性 | |||
---|---|---|---|
描述 | Saxagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor. DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased[3]. Generally, saxagliptin has similar efficacy compared with most oral antidiabetic drugs and may be more effective than acarbose, while having a better safety profile than both acarbose and sulfonylureas[4]. Saxagliptin has a shorter half-life than the other dipeptidyl-peptidase IV inhibitors, so it might be a better choice among drugs in this class for nursing mothers[5]. Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy. Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting EGFR[6]. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
Caco-2 cells | Function assay | Inhibition of human DPP4 expressed in Caco-2 cells, Ki=0.6 nM | 17034148 |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01646320 | - | Completed | - | - | |
NCT02377388 | Platelet Aggregation During Ac... 展开 >>ute Myocardial Infarction 收起 << | Phase 3 | Recruiting | December 2019 | Brazil ... 展开 >> Heart Institute(InCor)-Acute Coronary Care Unit Recruiting São Paulo, SP, Brazil, 01406000 Contact: Paulo R Genestreti, MD 55 11 2661-5058 paulo.gen@ig.com.br Principal Investigator: Jose C Nicolau, MD,PhD Sub-Investigator: Paulo R Genestreti, MD 收起 << |
NCT01646320 | Type 2 Diabetes | Phase 3 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.17mL 0.63mL 0.32mL |
15.85mL 3.17mL 1.59mL |
31.70mL 6.34mL 3.17mL |
参考文献 |
---|